Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095774 | 0.87 | GBA1 (0.61) | GBA1MAPTABCG2TSHRCYP1A2 | |
| SCHEMBL4085133 | 0.87 | MEN1 (0.64) | GBA1MAPTABCG2TSHRCYP1A2 | |
| SCHEMBL4089767 | 0.84 | GBA1 (0.60) | GBA1MAPTTSHRCYP1A2CYP3A4 | |
| SCHEMBL4090816 | 0.81 | HIF1A (0.68) | GBA1MAPTTSHRCYP1A2CYP3A4 | |
| SCHEMBL4090401 | 0.81 | GBA1 (0.64) | GBA1MAPTABCG2TSHRCYP1A2 | |
| SCHEMBL4755935 | 0.80 | MAPT (0.56) | GBA1MAPTABCG2TSHRCYP1A2 | |
| SCHEMBL4094693 | 0.79 | MEN1 (0.72) | GBA1MAPTABCG2TSHRCYP1A2 | |
| SCHEMBL1084633 | 0.77 | MEN1 (0.56) | GBA1MAPTTSHRCYP1A2CYP3A4 | |
| SCHEMBL4097324 | 0.76 | ABCB1 (0.70) | GBA1MAPTTSHRCYP1A2CYP3A4 | |
| SCHEMBL4085201 | 0.76 | ABCB1 (0.53) | GBA1MAPTTSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | GBA1 2059/4885MAPT 4125/4885ABCG2 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.